Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer-Reference-Cited by-同舟云学术

Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer

Published:2019-08-05 Issue:9 Volume:12 Page:831-840
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Santarpia Mariacarmela¹,Menis Jessica²³,Chaib Imane⁴,Gonzalez Cao Maria⁵,Rosell Rafael⁴⁵

Affiliation:

1. Medical Oncology Unit, AOU Policlinico “G. Martino”, Department of Human Pathology of Adult and Evolutive Age “G.Barresi”, University of Messina, Messina, Italy

2. Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy

3. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy

4. Catalan Institute of Oncology, Germans Trias i Pujol University Hospital, Badalona, Spain

5. Dr. Rosell Oncology Institute (IOR), Dexeus University Hospital, Barcelona, Spain

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2019.1649136

Reference51 articles.

1. Cancer statistics, 2019

2. Large-scale screening for somatic mutations in lung cancer

3. Immunotherapy in NSCLC: A Promising and Revolutionary Weapon

4. Recent developments in the use of immunotherapy in non-small cell lung cancer

5. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro investigation of the binding characteristics of dacomitinib to human α 1-acid glycoprotein: Multispectral and computational modeling;Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy;2024-06

2. Design and synthesis of gefitinib derivatives as potential drugs for cancer treatment: antiproliferative activity, molecular docking, and ADMET prediction;Letters in Drug Design & Discovery;2023-08-10

3. Comprehending the intermolecular interaction of dacomitinib with bovine serum albumin: experimental and theoretical approaches;Journal of Biomolecular Structure and Dynamics;2023-06-08

4. Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions;Therapeutic Delivery;2022-03

5. The role of salvage surgery in the treatment of a gefitinib-resistant non-small cell lung cancer patient: a case report;Journal of Thoracic Disease;2021-07